Nomura Holdings
CHRS icon

Nomura Holdings’s Coherus Oncology CHRS Stock Holding History

Nomura Holdings’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-68,300
Closed -$227K – 1678
2023
Q4 		$227K Buy
68,300
+47,290
+225% +$127K ﹤0.01% 1546
2023
Q3 		$78.6K Sell
21,010
-45,407
-68% -$210K ﹤0.01% 1277
2023
Q2 		$284K Sell
66,417
-1,883
-3% -$11.1K ﹤0.01% 1129
2023
Q1 		$467K Buy
68,300
+22,626
+50% +$176K ﹤0.01% 1143
2022
Q4 		$360K Hold
45,674
– – ﹤0.01% 1027
2022
Q3 		$441K Buy
45,674
+21,524
+89% +$218K ﹤0.01% 1126
2022
Q2 		$189K Sell
24,150
-34,150
-59% -$297K ﹤0.01% 1290
2022
Q1 		$749K Buy
58,300
+28,462
+95% +$362K ﹤0.01% 1195
2021
Q4 		$476K Sell
29,838
-5,961
-17% -$104K ﹤0.01% 1526
2021
Q3 		$591K Buy
35,799
+11,988
+50% +$176K ﹤0.01% 1329
2021
Q2 		$330K Sell
23,811
-9,190
-28% -$130K ﹤0.01% 1558
2021
Q1 		$482K Buy
+33,001
New +$560K ﹤0.01% 1373

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Nomura Holdings's CHRS Position: Q1 2024 in Review

Nomura Holdings sold out of Coherus Oncology (CHRS) in Q1 2024, closing a stake of 68,300 shares — an estimated $227K sold.

Nomura Holdings first reported a position in CHRS in Q1 2021 and held it in 12 quarters. The position peaked at $749K in Q1 2022. 137 funds tracked by Wall St. Rank hold CHRS as of Q1 2024.

  • Nomura Holdings reported no remaining Coherus Oncology position as of Q1 2024 after selling out during the quarter.
  • Nomura Holdings sold 68,300 Coherus Oncology shares in Q1 2024, an estimated $227K.
  • Nomura Holdings first reported a position in Coherus Oncology in Q1 2021 and held it in 12 quarters.
  • Nomura Holdings's Coherus Oncology position peaked at $749K in Q1 2022.
  • 137 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2024.

Based on Nomura Holdings's 13F filing for Q1 2024, filed 15 May 2024.